Results 81 to 90 of about 105,036 (275)
Linkages and Spillovers from Foreign Ownership in the Indian Pharmaceutical Firms [PDF]
The paper examines the spillover and linkage effects from the presence of foreign firms in the Indian pharmaceutical industry. A comprehensive panel data consisting of nearly 200 firms from 1989 to 2000 was used in the current study.
Sanja Samirana Pattnayak +1 more
core
FEBS Open Bio, EarlyView.We investigated the toxicity of 12 active compounds commonly found in herbal weight loss supplements (WLS) using human liver and colon cell models. Epigallocatechin‐3‐gallate was the only compound showing significant toxicity. Metabolic profiling revealed protein degradation, disrupted energy and lipid metabolism suggesting that the inclusion of EGCG ...
Emily C. Davies +3 more
wiley +1 more source
Reaching for Mediocrity: Competition and Stagnation in Pharmaceutical Innovation [PDF]
, 2018 Patents might incentivize invention but they do not guarantee firms will invest in projects that maximize social utility. We model how risk-neutral firms’ ability to obtain substantial private returns on marginal new technologies causes them to “reach ...
Le, Son, Sukhatme, Neel U.
core +1 more source
FEBS Open Bio, EarlyView.A tri‐culture of iPSC‐derived neurons, astrocytes, and microglia treated with ferroptosis inducers as an Induced ferroptosis model was characterized by scRNA‐seq, cell survival, and cytokine release assays. This analysis revealed diverse microglial transcriptomic changes, indicating that the system captures key aspects of the complex cellular ...
Hongmei Lisa Li +6 more
wiley +1 more source
Perverse Results from Pharmaceutical Patents in the United States. [PDF]
IIC Int Rev Ind Prop Copyr Law, 2021 Grimes W.
europepmc +1 more source
Pharmaceutical Patents: Incentives for R&D or Marketing? [PDF]
We analyse how a patent-holding pharmaceutical firm may strategically use advertising of existing drugs to affect R&D investments in new (differentiated) drugs, and thereby affect the probability distribution of future market structures in the industry ...
Kurt R. Brekke, Odd Rune Straume
core
Bayer AG v. Housey Pharmaceuticals: Protection for Biotechnological Research Tools under Section 271(g) Found Wanting [PDF]
, 2005 [Excerpt] Research tools, a subset of biotechnological inventions protected by process patents, are “tools that scientists use in the laboratory, including cell lines, monoclonal antibodies, reagents, animal models, growth factors, combinatorial ...
Barthalow, Matthew
core +1 more source
FEBS Open Bio, EarlyView.The inhibition of mitochondrial dihydroorotate dehydrogenase (DHODH) impairs syncytialization and induces cellular senescence via mitochondrial and endoplasmic reticulum stress in human trophoblast stem cells, elevating sFlt1/PlGF levels, a hallmark of placental dysfunction in hypertensive disorders of pregnancy.
Kanoko Yoshida +6 more
wiley +1 more source
Insurance and Incentives for Medical Innovation [PDF]
This paper studies the interactions between health insurance and the incentives for innovation. Although we focus on pharmaceutical innovation, our discussion applies to other industries producing novel technologies for sale in markets with subsidized ...
Alan M. Garber +2 more
core
A New Paradigm for Intellectual Property Rights in Software [PDF]
, 2005 A Winter 2004 article by Bradford L. Smith and Susan O. Mann of Microsoft published in The University of Chicago Law Review suggests that the development and growth of the software industry in the U.S.
Webbink, Mark H.
core +1 more source